Zebularine is a novel potent inhibitor of both cytidine deaminase and DNA methylation.
Abstract
Zebularine is a novel potent inhibitor of both cytidine deaminase and DNA methylation.
We examined the effect of zebularine on mammary tumor growth in genetically engineered MMTV-PyMT transgenic mice that develop mammary tumors at 60 days of age with 100 percent penetrance. The MMTV-PyMT transgenic mice were randomized at 46 days of age into control (n=25) and zebularine (n=25) treatment groups and monitored for parameters of tumor growth. Zebularine was administered at 5 mg/ml in drinking water. We observed a significant delay in the growth of mammary tumors in zebularine treated mice with a statistically significant reduction (p = 0.0135) in total tumor burden at 94 days of age when the mice were sacrificed. After 48 days of zebularine treatment the tumors were predominantly necrotic compared to untreated animals. In addition, a high apoptotic index by TUNEL assay was observed as early as 13 days following treatment. Immunoblot analysis showed depletion of DNMT1 and partial depletion of DNMT3b after zebularine treatment. Microarray analyses of global gene expression identified upregulation of twelve methylation regulated genes as well as a set of candidate cancer genes that participate in cell growth and apoptosis. In summary, zebularine inhibits the growth of spontaneous mammary tumors and causes early onset of tumor cell necrosis and apoptosis in a genetically engineered mouse model of breast cancer. Defining the parameters of zebularine-mediated tumor inhibition may advance the future development of DNA methyltransferase inhibitors as an effective cancer treatment.
Introduction
Hypermethylation is commonly detected within the promoter and other regulatory regions of many cancer-associated genes in primary tumor biopsies and derived tumor cell lines (1) . Since aberrant hypermethylation is associated with reversible gene silencing, the development of pharmacologic inhibitors of DNA methylation has provided a rational approach for cancer therapy. Specific inhibitors of DNA methylation such as 5-Azacytidine (5-Aza-CR) and its deoxy analog, 5-Aza-2'deoxycytidine (5-Aza-CdR) have been studied for decades, however, both drugs are toxic in vitro and in vivo, and have been difficult to administer due to their low stability in aqueous solution (2) (3) (4) .
Zebularine is a novel DNMT inhibitor, which was developed as a more stable and less toxic drug (5) . Zebularine, similar to 5-Aza-CR and 5-Aza-CdR, incorporates into DNA and forms a covalent irreversible complex with DNA methyltransferases (DNMTs) (6) preventing the enzyme from methylating position five of cytosines clustered in regulatory CpG islands. Recent studies demonstrated the ability of zebularine to sustain the demethylation state of the 5' region of the tumor suppressor gene CDKN2A/p16 and other methylated genes in T24, HCT15, CFPAC-1, SW48 and HT-29 cells ȋȌ. It was also reported that zebularine inhibits growth of cancer cell lines but not normal cells (7) . A recent study showed that zebularine treatment inhibited the growth of lung tumor cells with hypermethylated CDKN2A gene while it had no effect on lung cancer cells with homozygous deletion of CDKN2A (8) , suggesting a link with reactivation of CDKN2A. In addition, oral or intraperitoneal administration of zebularine in the EJ6 bladder cancer xenograft model in nude mice reduced tumor growth with minimal toxicity (9) .
In the present study, the anti-tumor growth effect of zebularine was studied in a genetically engineered mouse model that develops mammary tumors within 60 days with 100% penetrance. MMTV-PyMT-transgenic mice express polyomavirus middle T antigen and develop spontaneous multifocal mammary tumors with a rapid conversion of mammary epithelium to the malignant state (10) . Epigenetic silencing of tumor suppressor and growth regulatory genes has been implicated in breast cancer (11) (12) (13) (14) (15) and dysregulated DNA methyltransferase activity may also be a contributing factor to breast cancer development (16) . Therefore, to determine the ability of zebularine to prevent or treat breast cancer, we tested if daily oral treatment with zebularine affects mammary tumor growth in these MMTV-PyMT mice. We observed a significant delay in tumor growth and a reduction of total tumor burden in the zebularine treated mice. We also showed depletion of DNA methyltransferases in tumors excised from zebularine treated mice and identified upregulation of 12 genes previously characterized as silenced by DNA hypermethylation.
A microarray analysis of RNA extracted from excised mammary tumors from zebularine treated and control mice also identified a set of dysregulated genes that function in cell cycle, apoptosis, cell growth and signaling pathways that correspond to genes previously shown to play a role in tumor formation in MMTV-PyMT mice. Finally, we demonstrated that zebularine treatment resulted in the induction of necrosis and apoptosis in spontaneously developed tumors with no apparent toxicity to the mice. 
Drug treatment in vivo
For the zebularine treatment, the mice were treated via drinking water by solubilizing zebularine at 5 mg/ml in water. To encourage consumption, sucrose was added to the drinking water at 2 g/100 ml. Vehicle control mice received sucrose-supplemented drinking 6 water. Prior animal studies (17) with zebularine demonstrated that daily i.p. doses in excess of 900 mg/kg were tolerated. To study a protracted course of daily zebularine we selected drinking water as a clinically relevant and less stressful way to provide continuous exposure. Based upon the typical mouse water consumption rate of 150 ml of water per kg of body weight, we elected to administer the agent at 5 mg/ml of water thereby producing a daily zebularine dose of 750 mg/kg.
In addition, to quantitate zebularine levels in the mice, plasma samples were collected from mice undergoing treatment with zebularine via the drinking water (5 mg/ml) at 7, 14 and 21 days of treatment (n = 3 per time point). Samples were found to contain average zebularine levels of 9.56 μM, 16.0 μM and 31.8 μM at days 7, 14, and 21, respectively.
This demonstrates that zebularine does accumulate with chronic dosing via the drinking water. Untreated controls (n = 10) had zebularine levels of 0.0 μM.
Histological evaluation
Tumor tissues collected from zebularine treated and untreated animals were stored at -80°C. For slide preparation, a small piece of tumor was excised and frozen tumors were transferred from -80°C to -20°C overnight. Tumor tissues were fixed for 24 hr in 10%
formaldehyde solution, transferred to 70% ethanol, and embedded in paraffin. Sections were cut (5 ȝm) and mounted on salinated slides for hematoxylin and eosin (H&E) staining (Histoserv Inc). Tumor necrosis was evaluated by two investigators on H&E stained slides.
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL)
The TUNEL assay (R&D Systems, Minneapolis, MN) was performed on formalin-fixed and paraffin-embedded sections as previously described (18) . An avidin-conjugated horseradish peroxidase bound to the biotinylated DNA fragments was used to generate a brown precipitate in the presence of diamenobezidine (Vector Laboratories Inc, Burlingame, CA). A nuclease-treated tumor specimen section was used as a positive control, and the same tumor section without nuclease treatment was used as a negative control. Tumor apoptosis was analyzed quantitatively using Automated Cellular Imaging System (ACIS; DAKO, CA) as described previously (19) . A hot spot feature of the ACIS was used to identify sites of apoptotic labeling where six areas of tumor were scored with a 40X tool or a free-scoring tool. The instrument calculated an average labeling percentage.
Immunoblot analysis
Excised tumor was resuspended in 1 ml of RIPA buffer containing protease inhibitors as recommended by the manufacturer (Santa Cruz Biotech, Kit # sc-24948). Tumors were cut with scissors to small pieces and were homogenized for 30 to 60 seconds to disperse the tissue. Cell extracts were incubated on ice for 1 hr, and centrifuged at full speed in a micro GeneChip scanner 3000, and analyzed using Microarray Suite 5.0 software (MAS5, Affymetrix Inc., Santa Clara, CA). Mean signal intensity was scaled to a target value of 500 using all probe sets. Normalization, gene filtering, comparative gene expression, and hierarchical clustering analysis were done using BRB Array Tools software developed by the Biometric Research Branch of the National Cancer Institute. The genes for all analyses were filtered by requiring the spot intensity to be >10. Each array was normalized using the median over the entire array. Only genes that reported values in at least 75% of the samples were included for further analysis. The Class Comparison Tool, using Univariate TwoSample T-test with random variance model and permutations of the class labels was applied to all probes that passed the signal intensity and missing-value filters. A total of 9 868 genes (representative of 1.8% genes) with a minimum 1.5-fold expression change in either direction from the median value of the gene (p < 0.05) with the signal intensity > 200 were selected. Over-representation analysis was performed using EASE software.
Expressed genes in the ontology terms having EASE score < 0.05 were selected. The gene ontology terms were ranked by the significance of over-representation. This model takes into account not only the relative changes (i.e. fold change), but also the absolute expression, thereby cleaning up relatively 'noisy' data from very weakly expressed genes. 
Pyrosequencing analysis
Sodium bisulfite conversion of 1μg of genomic DNA harvested from normal murine mammary epithelium and mammary tumor specimens was carried out with the EZ DNA The beads were harvested using a vacuum preparation workstation and appropriate sequencing primer added to a final concentration of 330 nM. The sequencing primers were annealed to the template by incubating the samples at 80°C for 2 min and cooled at RT for 10 min prior to analysis. Primer sequences for Twist2 were TGGAtAATAAGATGAttAGtTGtAGt for the forward primer (also used as the sequencing primer) and tAAGttAGGGTAGGTGtTG for the reverse primer (lower case indicates bisulfite converted cytosines).
Pyrosequencing was conducted using a PyroMark MD system (Qiagen), and sequence analysis conducted using the supplied Pyro Q-CpG software by Biotage AB.
Statistical analysis
The significance of the comparisons between different treatment groups was determined by Student's T-test. Statistical analysis of tumor burden was performed using the nonparametric Mann-Whitney U-test. (Fig. 1D, p<0 .05 and 1E, p<0.01). Mice were treated up to 94 days of age (total of 48 days of zebularine treatment) at which time the mice were sacrificed and the total tumor burden was excised and weighed. We also found a statistically significant reduction in total tumor burden in zebularine treated as compared to control mice at 94 days of age (Fig. 1F, 
Zebularine treatment induces necrosis and apoptosis in mammary gland tumors
To determine the effect of zebularine on tumor growth we first examined the morphology of tumors in treated and control mice. After 48 days of zebularine treatment, areas of tumor necrosis (acellular pink staining region) comprised about 50% of the tissue section ( Fig. 2A, images a and c) . In contrast, poorly differentiated mammary tumor cells without necrosis were observed in the untreated animals ( Fig. 2A, images b and d) . This data suggests that tumor cell death induced by zebularine treatment may have contributed to the delay in detactble tumor growth in mice. To confirm that cell death was a result of induction of apoptosis, we performed a TUNEL assay on tumors derived from zebularine treated and untreated control animals. Apoptotic cells were observed as early as 13 days after zebularine treatment (Fig. 2B) . At day 13, a high percentage of apoptotic cells were observed in tumors examined in all four mice treated with zebularine (10, 11, 56 and 84%) (Fig. 2C) . A negligible level of apoptotic cells was found in tumors derived from four control animals (0, 1.6, 2.0 and 2.2%) (Fig. 2C p=0.057) . At day 48, all three tumors derived from the zebularine treated animals showed a high apoptotic index (Fig. 2C ) while a significantly lower apoptotic index was found in tumors derived from three control animals tested (Fig. 2C p<0.05 ).
Depletion of DNMT1a and DNMT3b protein levels by zebularine
Since it has been shown that zebularine treatment of tumor cell lines resulted in depletion of DNMT1 and a partial depletion of DMNT3b in vitro (7), we set out to determine if from untreated mice, we observed a near complete depletion of DNMT1 and a partial depletion of DMNT3b 23 days after zebularine treatment ( Fig. 3A and B) . We found that tumors derived from all three zebularine treated mice examined showed a near complete depletion of DMNT1 (Fig. 3A, lanes 4-6) as compared to tumors from untreated animals that contain high level of DNMT1 protein (Fig. 3A, lanes 1-3 and Fig. 3C, lanes 4 and 5) .
In addition, two of three zebularine treated animals show depletion of DMNT3b ( We also compared the levels of DNMT1 and DNMT3b in normal mammary glands versus mammary tumors. We found that levels of DNMT1 and DNMT3b are lower in normal mammary glands (Fig. 3C, lanes 1-3) as compared to high levels observed in untreated tumors (Fig. 3A, lanes 1-3 and B, lanes 1-3 and Fig. 3C, lanes 4 and 5) suggesting that DNMT1 and DNMT3b are induced during tumorigenesis in MMTV-PyMT mice.
Alteration of global gene expression by zebularine treatment
To identify potential molecular pathways involved in the delay of tumor development by zebularine treatment, we compared the global gene mRNA expression profiles between tumors isolated from untreated and zebularine-treated mice at day 13 (n=3), day 23 (n=3), and day 48 (n=3). We detected 868 genes differentially expressed at these time-points in zebularine-treated vs untreated samples. This included 194 genes that were up-regulated 
and 188 genes down-regulated at 13 days after treatment (Supplementary Tables 1 and 2) , 100 genes up-regulated and 120 genes down-regulated 23 days after treatment (Supplementary Tables 3 and 4) , and 158 genes up-regulated and 108 genes downregulated 48 days after treatment (Supplementary Tables 5 and 6 ). In this data set, we included only genes that were at least 1.5 fold differentially regulated and for which statistical significance (p<0.05) was reached.
To search for cancer relevant signaling pathways altered by zebularine treatment in vivo, we used EASE software (http://EaseSoftware.com) and classification of 868 genes by KEGG database (http://www.genome.jp/kegg) and Gene ontology (GO) (http://www.geneontology.org). We found that zebularine treatment significantly regulated expression of genes that are involved in DNA methylation, apoptosis, cell cycle, tumorsuppression and metastasis. Further, altered expression of components of the AKT, Src and Ras cancer signaling pathways (Table 1 and 2) was also observed. We also noted that 12 genes previously characterized as regulated by aberrant hypermethylation were upregulated by zebularine treatment (1.5 to 2.4 fold) when compared to untreated controls (Table 1) . Specifically, we observed increased expression of CCND2/Cyclin D2, CDKN1A/p21, Lamin A, Sfrp1, Becn1, Twist2, Ptgs2, H19, Myod1, Gelsolin (Gsn), Igfbp6 and TGFβi (full names and gene IDs are shown in Table 1 ). In addition, two genes regulated by DNA methylation, Wif1 (11) and HDAC11 (21), were down-regulated 3.2 fold and 1.5 fold respectively (Table 2) .
Since it has been previously reported that expression of the cell cycle regulator Cdc25c was increased in MMTV-PyMT tumors (22), we also examined the effect of zebularine on the expression of cell cycle regulated genes as a mechanism for tumor growth inhibition. 
As expected, we observed that after zebularine treatment, Cdc25c and other genes required for cell proliferation such as CDK4 and Cdc20, were down-regulated (Table 2) , while tumor suppressor genes such as CDKN1A, Becn1, Sfrp1 were up-regulated (Table 1 ). In addition, apoptosis-related proteins such as Casp4, Sfrp1 and IGFbp6 were also upregulated (Table 1 ). We also found that zebularine treated MMTV-PyMT mice showed an increased prostaglandin 2 (Ptgs2) expression in tumors after 23 days of treatment, which correlated with increased Sfrp1 expression 48 days after treatment. This is an interesting observation because Sfrp1 promotes apoptosis (23) and was shown to be induced 38-fold following Ptgs2 treatment of osteoblasts (24) .
Molecular analysis of tumors arising in MMTV-PyMT transgenic mice showed activation of phosphatidylinositol 3-kinase (PI3K) (25, 26) , Src (27) and Ras (28) signaling pathways.
Our microarray profile revealed that genes involved in the tumorigenic PI3K/Akt signaling pathways that are associated with MMTV-PyMT tumor formation, such as Akt1, PIK3cd and PIK3c2a (29) , were down-regulated by zebularine treatment (Table 1 and Supplementary Table1). In addition, genes involved in Src-and Ras-signaling such as Catns, Rasal1, Tnfrsf19 and Tnfrsf11a were also down-regulated after 13 and 23 days of zebularine treatment (Table 2 and Supplementary Tables 2 and 4 
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We selected 6 genes from the microarray gene list for validation using quantitative reverse transcription-PCR. These genes were chosen because their expression was either known to be regulated by aberrant hypermethylation or because they play a direct role in the regulation of DNA methylation. H19, CDKN1A and Ptgs2 were up-regulated in the microarray analysis and were confirmed to be up-regulated by real-time RT-PCR analysis (Fig. 4A) . Wif1 was down-regulated in microarray analysis and this was confirmed by realtime RT-PCR (Fig. 4A) . In addition, the expression of DNMT3b was down-regulated 1.3 fold in the microarray analysis although it is not listed in Table 1 since the cut-off was 1.5 fold down-regulation in selecting our data set (Fig. 4A ). Altered expression of only two genes (HIF-1 and DAPK1), which were down-regulated 1.5 fold in microarray analysis, could not be confirmed by RT-PCR analysis (data not shown). The expression levels of H19, CDKN1A and Ptgs2, Wif1 and DNMT3b genes as detected by microarray and reverse transcription-PCR, were highly correlated with R 2 = 0.94 (Fig. 4B) .
Comparison of gene silencing and methylation status between normal mammary glands, mammary tumors and tumors from zebularine treated mice
PyMT mice treated with zebularine for 23 days (Fig. 5A and supplemental Table 7 ).
Consistent with microarray results, upregulation of Twist2 was observed in mammary tumors from 94 day old zebularine treated MMTV-PyMT mice (48 days of treatment)
while no upregulation of Twist2 in tumors dissected from 69 day old (23 days of treatment) zebularine treated mice was observed (Supplemental Table 7 ).
To investigate the correlation of DNA methylation in silencing and reactivation of Twist2 expression in normal mammary glands ( glands 2&3 and gland 4 measured separately), mammary tumors, and tumors in mice treated with zebularine, the methylation status of the Twist2 gene was determined. Specifically, pyrosequencing was used to quantitatively measure cytosine methylation at 4 distinct CpG dinucleotides within the dense CpG island present at the mouse Twist2 locus (Fig. 5B ). We measured low Twist2 methylation at each of the four CpG sites interrogated in normal mammary gland tissues (3.8 % average overall) ( 
Discussion
We have demonstrated that the DNA methylation inhibitor, zebularine, has anti-tumor effects in a genetically engineered breast cancer mouse model. We found that zebularine treatment caused a significant delay of tumor formation and induced necrosis and apoptosis in mammary tumors that developed in MMTV-PyMT transgenic mice. Genetically engineered mouse models (GEMMs) recapitulate many aspects of human cancer and more closely resemble tumor histology and microenviromental features of naturally occurring cancers (32) than the more common xenograft model system. Moreover, recent studies show that GEMMs predicted clinical trial outcomes when standard chemotherapy either alone or in combination with targeted agents was used (33). Since xenograft models do not reliably predict human clinical outcomes (34), GEMMs may lay a framework for predicting outcomes by studying therapeutic response and drug resistance. In this study, we chose the MMTV-PyMT GEMM (25) since these mice develop mammary tumors with a 100% incidence rate. As DNA methylation appears to play an important role in modulation of cancer-associated genes in sporadic breast cancer (11-13, 15, 35, 36) Using a microarray screening approach we detected a total of 12 candidate genes (Table   1) was associated with loss of the DNMT1 in mouse fibroblasts (38) . Interestingly, the hypermethylated Sfrp1 gene can also be induced by 5-aza-deoxycytidine (5-aza-dC). This drug causes inhibition of the transformed phenotype in breast (13) and GI cancers (39) (40) (41) .
In addition, zebularine treatment induced CCND2/Cyclin D2, an important regulator of the G1/S cell cycle transition. Cyclin D2 mRNA and protein are absent in breast cancer cell lines and in primary breast cancers whereas cultured normal breast epithelial cells had abundant expression (42) (43) (44) . The fact that cyclin D2 expression is silenced by hypermethylation in human breast tumors and our observation that zebularine induced Cyclin D2 gene expression in mammary GEMM tumors suggests that induction of Cyclin D2 may participate in breast tumor growth inhibition.
CDKN1A/p21, known to be activated after DNA damage to arrest cell growth (45, 46) was also up-regulated in MMTV-PyMT mice tumors after 23 days of zebularine treatment confirming previous observations that CDKN1A/p21 was induced by zebularine in MCF-7 breast cancer cells (47) . We did not observe, however, the re-activation of CDKN2A/p16 gene in tumors derived from zebularine treated MMTV-PyMT mice. CDKN2A/p16 gene was found previously to be activated by zebularine in non-breast human cancer cell lines (6) (7) (8) (9) . Although CDKN2A/p16 was shown to be hypermethylated in 5 out of 16 breast cancer tissue samples, and in 1 out of 6 breast cancer cell lines, there are no reports in literature indicating induction of p16 mRNA or protein levels by demethylating agents in breast cancer cells (48) . In summary, zebularine, a known DNMT inhibitor, depletes DNMTs in vivo and re-activates (at least) 12 genes silenced by aberrant DNA hypermethylation in a breast cancer mouse model. 
We also observed that zebularine treatment altered the expression of genes that are involved in cell proliferation, cell cycle regulation, apoptosis and signaling. In summary, genes that are required for cell proliferation (Cdc25c, CDK4, Cdc20) were down-regulated (Table 2) , while tumor suppressor genes which undergo tumor specific hypermethylation (CDKN1A, Becn1, Sfrp1) were up-regulated (Table 1) . Zebularine treatment also resulted in apoptotic cell death, which was associated with upregulation of Casp4, Sfrp1 and CDKN1A ( Table 1 ). The apoptosis and tumor necrosis induced by zebularine treatment may have contributed to the delay in tumor growth in MMTV-PyMT transgenic mice.
Although we do not know which combination of the zebularine regulated genes may have directly contributed to delay of tumor growth, we do notice that the same genes that are reexpressed by zebularine treatment have been found to induce apoptosis, and inhibit tumor cell growth in breast cancer (13, (49) (50) (51) (52) . It remains to be determined which of these genes might play a direct role in the inhibition of the tumor growth and induction of apoptosis in MMTV-PyMT mice treated by zebularine.
The mechanism of tumor formation in MMTV-PyMT transgenic mice has been well characterized and reported to involve the activation of PI3K/Akt (25, 26) , Src (27) and Ras (22, 28) pathways. PyMT binds PI3K to activate downstream effectors of PI3K/Akt (26) and a recent finding shows that Akt1 ablation delays the development of mammary adenocarcinomas in MMTV-PyMT mice (53). The results from our microarray profile revealed that Akt1 and other genes involved in this pathway such as Pik3cd and Pik3c2a were down-regulated by zebularine treatment (Table 1 and Supplementary Table1 ). In addition, we showed that proteins such as Catns, Rasal1, Tnfrsf19 (22) , and Tnfrsf11a, each of which function in Src and Ras signaling, were differentially down-regulated 
following zebularine treatment (Table 2 and Supplementary Tables 2 and 4 ). In addition, Cdc25C, a critical cell cycle regulator, and metalloproteases MMP-2, -3 and -13 were increased in MMTV-PyMT tumors (22, 30) . We found that expression of Cdc25c and other cell cycle regulators including Cdc20 and CDK4 as well as expression of MMP 12 and MMP 13, was down-regulated in zebularine treated MMTV-PyMT mammary tumors.
Moreover, expression of Gelsolin (Gsn) was found to be decreased in PyMT tumors (22) . 
